Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Genetic Screens02:46

Genetic Screens

5.5K
Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing  genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
5.5K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

9.9K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
9.9K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.6K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.6K
What is Genetic Engineering?00:49

What is Genetic Engineering?

79.5K
Overview
79.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quantifying Market Trajectories: A Study of Pharmaceutical Sales Uptake Curves and Related Parameters.

Therapeutic innovation & regulatory science·2026
Same author

The Health of Nations Fund: Financing global drug development.

PLOS global public health·2026
Same author

Estimating the global inventory of deprioritized clinical-stage drug development programs: Toward a market for shelved assets.

Drug discovery today·2026
Same author

Immune-driven stromal inflammation in pancreatic cancer within a microfluidic platform.

Biofabrication·2026
Same author

Establishing a commercial solution for extremely rare genetic diseases.

Nature biotechnology·2026
Same author

High-Frame-Rate Low-Noise Global Shutter CMOS Image Sensor for High-Speed Machine Vision.

Sensors (Basel, Switzerland)·2026
Same journal

Targeting the GLP-1 receptor pathways for dual management of obesity and depression.

Drug discovery today·2026
Same journal

Chemical intervention strategies targeting MYC for cancer therapy.

Drug discovery today·2026
Same journal

How many protein pairs can we chemically target?

Drug discovery today·2026
Same journal

From trial-and-error to inverse design: how AI is redefining drug delivery systems.

Drug discovery today·2026
Same journal

Critical evaluation of the key mediators causing life-threatening symptoms during human anaphylaxis.

Drug discovery today·2026
Same journal

A20 as a novel immunoregulatory target for neuroinflammation.

Drug discovery today·2026
See all related articles

Related Experiment Video

Updated: Jan 8, 2026

Author Spotlight: Cost-Effective Transcriptomic Drug Screening - Unlocking New Targets
06:40

Author Spotlight: Cost-Effective Transcriptomic Drug Screening - Unlocking New Targets

Published on: February 23, 2024

1.7K

Genetic Targets, Financial Creativity: BridgeBio's Model for Sustainable Drug Development.

Chinmay Shukla1, Irwin Tendler1, Neil Kumar1

  • 1BridgeBio Pharma, Palo Alto, CA, United States.

Drug Discovery Today
|December 13, 2025
PubMed
Summary
This summary is machine-generated.

BridgeBio

More Related Videos

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
A Manual Small Molecule Screen Approaching High-throughput Using Zebrafish Embryos
07:45

A Manual Small Molecule Screen Approaching High-throughput Using Zebrafish Embryos

Published on: November 8, 2014

18.2K

Related Experiment Videos

Last Updated: Jan 8, 2026

Author Spotlight: Cost-Effective Transcriptomic Drug Screening - Unlocking New Targets
06:40

Author Spotlight: Cost-Effective Transcriptomic Drug Screening - Unlocking New Targets

Published on: February 23, 2024

1.7K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
A Manual Small Molecule Screen Approaching High-throughput Using Zebrafish Embryos
07:45

A Manual Small Molecule Screen Approaching High-throughput Using Zebrafish Embryos

Published on: November 8, 2014

18.2K

Area of Science:

  • Biotechnology
  • Pharmaceutical Sciences
  • Drug Development

Background:

  • Biotech drug development is inherently risky and capital-intensive.
  • Balancing scientific progress with financial viability is crucial.

Purpose of the Study:

  • To present BridgeBio's portfolio-based operating model.
  • To analyze its integration of genetically validated targets, operational discipline, and financial structuring.
  • To compare this model with traditional biotech archetypes.

Main Methods:

  • Case study analysis of BridgeBio's operational model.
  • Comparative analysis against single-asset, platform-based, and venture-creation models.
  • Literature review on biopharmaceutical innovation strategies.

Main Results:

  • BridgeBio's model enables rapid and scalable drug development.
  • The portfolio approach enhances resilience and efficiency in biopharmaceutical innovation.
  • Contrasts with traditional models highlight unique advantages.

Conclusions:

  • Portfolio-based strategies offer a viable alternative for biotech innovation.
  • Integration of scientific and financial strategies is key to success.
  • BridgeBio's model provides a framework for efficient drug development.